N/A N=1,175 Toronto Thromboprophylaxis Patient Safety Initiative
Venous Thromboembolism
Primary: Percentage of Patients Prescribed Appropriate VTE Prophylaxis — 64; 62; 67; 54 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8,256 Epidemiology of Thromboembolism Disease: A Cohort Study
Vascular Diseases · Embolism and Thrombosis · Phlebitis
Primary: Percentage of Participants Who Developed a New or Recurrence of Venous Thromboembolism (VTE) — 8.94 percentage of participants
Phase 3 N=1,046 Cancer Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE) · Deep Vein Thrombosis (DVT) · Pulmonary Embolism (PE)
Primary: Number of Participants With Adjudicated Recurrent Venous Thromboembolism (VTE) or Major Bleeding Event — 67; 71 Participants — p=0.0056
Phase 3 N=5,395 Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Incidence of Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or VTE-Related Death During 6 Months of Treatment — 0.0226; 0.0269 proportion…
Phase 3 N=2,856 Secondary Prevention of Venous Thrombo Embolism (VTE).
Thromboembolism
Primary: Composite of Recurrent VTE or VTE Death at 36 Months — 26; 18; 1404; 1408 Participants — p=0.0137
Phase 3 N=2,482 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
Venous Thrombosis
Primary: Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With…
Phase 2 N=82 Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis
Deep Vein Thrombosis
Primary: To Provide Estimates of the Specificity of [99mTc] ThromboView® in Patients With Excluded Initial DVT — 76.9; 65.4; 100; 96.2 % Specificity
Phase 3 N=692 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis
Deep Vein Thrombosis · Venous Thrombosis · Postphlebitic Syndrome
Primary: Cumulative Incidence of Post-Thrombotic Syndrome (Villalta Scale) — 157; 171 Participants — p=0.56
Phase 3 N=8,101 Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients
Venous Thromboembolism
Primary: Percentage of Participants With Composite Endpoint of Venous Thromboembolism [VTE] (Any Deep Vein Thrombosis [DVT], Non Fatal Pulmonary Embolism [PE]) and VTE-related…
N/A N=139 Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events
Pulmonary Thromboembolisms · Pulmonary Embolism
Primary: Correlation of 4DCT Identified Perfusion With SPECT/CT Identified Perfusion — 0.45 Spearman correlation
N/A N=13,945 Treatment Patterns Among Patients With Venous Thromboembolism in the United States
Venous Thromboembolism
Primary: Number of Participants Who Continued Treatment With Apixaban or Warfarin Following Discharge From the Hospital — 11966; 1979 Participants
Phase 3 N=1,343 Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
Venous Thromboembolism
Primary: Centrally Confirmed Symptomatic Recurrent Venous Thrombotic Events (VTE) Including Unexplained Death During the Intended Treatment Period — 3; 37 Participants — p=<0.0001
Phase 4 N=581 Chemoprophylaxis Plus Early Ambulation
Pulmonary Embolism · Thoracic Surgery
Primary: Incidence of Postoperative Pulmonary Embolism (PE) in Surgical Thoracic Patients Under Currently Used PE Prevention Strategies. — 3 Participants
Phase 2 N=84 A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis
Deep Vein Thrombosis · Venous Thrombosis
Primary: Relative Change From Baseline in Thrombus Volume Assessed by MRI [Using the Magnetic Resonance Venography (MRV) Method] — -46.6; -51.4 percentage of change
N/A N=266,890 The Risk of Venous Thromboembolism in Systemic Inflammatory Disorders: a United Kingdom (UK) Matched Cohort Study
Venous Thromboses · Venous Thromboembolism · Deep Vein Thrombosis
Primary: Risk of Venous Thromboembolism (VTE) — 335; 845; 132; 3804 Participants
N/A N=116 JETi Lower Extremity Venous Thrombosis
Venous Thrombosis
Primary: The Primary Effective Endpoint: Percent of Treated Vessel(s) With ≥ 75% Venous Thrombus Reduction in Modified Marder Score (From Pre-JETi to Final) — 84.5 percentage of…
Phase 3 N=2,539 Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
Thromboembolism
Primary: Number of Participants With Recurrent Symptomatic Venous Thromboembolism (VTE) and Deaths Related to VTE — 30; 27; 34; 32 Participants — p=<0.0001
Phase 3 N=3,463 Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
Thromboembolism · Arthroplasty, Replacement, Hip
Primary: Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period — 53; 75; 60 Participants — p=0.5648
N/A N=102 Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome
Acute Deep Vein Thrombosis
Primary: 2-year Change in Villalta Score — -1.5; -0.5 units on a scale — p=0.34
Phase 4 N=28 Treatment of Upper Extremity Deep-Vein Thrombosis
Deep-Vein Thrombosis
Primary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants
N/A N=407 Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism
Venous Thromboembolism · Venous Thrombosis
Primary: Number of Patients With Asymptomatic Venous Thrombosis of Lower Limbs as Detected by Duplex Ultrasound — 1; 34 Participants — p=<0.001
Phase 4 N=81 Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System
Deep Vein Thrombosis · Post-thrombotic Syndrome
Primary: Change From Baseline in Villalta Score at Day 30 Post-EkoSonic® Study Treatment Procedure — 15.5; -5.9 units on a scale
N/A N=754,745 The Incidence of Venous Thromboembolism in Atopic Dermatitis
Venous Thromboembolism · Atopic Dermatitis · Pulmonary Embolism
Primary: Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. — 2576; 7563 Participants
Phase 3 N=3,365 Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)
Pulmonary Embolism · Thromboembolism · Thrombosis
Primary: Number of Participants With the Composite of Fatal or Non-fatal Symptomatic Recurrent Venous Thromboembolism — 13; 17; 50; 8 participants — p=0.0001
N/A N=100 Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures
Deep Vein Thrombosis
Primary: Number of Participants With Post-operative Ultrasound Without Evidence of Thromboembolism — 91 Participants
Phase 3 N=300 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Gonadal Thrombosis
Primary: 6 Month Bleeding Rate — 0; 2.1 percentage of patients
Phase 3 N=12,019 A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
Heart Failure · Respiratory Insufficiency · Stroke Acute
Primary: Time From Randomization to First Occurrence of Composite of All Symptomatic Venous Thromboembolism (VTE) and VTE Related Death Adjudicated by Clinical Event Committee…
Phase 2 N=523 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
Venous Thromboembolism · Deep Vein Thrombosis · Total Knee Arthroplasty
Primary: Proportion of Subjects With Venous Thromboembolism Events. — 29.5; 26.1; 12.5; 9.1 percentage of participants — p=<0.001
N/A N=6,095 RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Venous Thromboembolism
Primary: Objective 1: Age — 61.5 years
N/A N=499 ClotTriever Outcomes (CLOUT) Registry
Deep Vein Thrombosis Leg · DVT · Chronic DVT of Lower Extremity
Primary: Primary Safety Endpoint: Proportion Participants With Major Adverse Events — 15 Participants